Skip to main content
Clinical Trials/NCT04257877
NCT04257877
Recruiting
Not Applicable

Targeted Proteomic Analysis in the Plasma of Children With Diabetes Type 1 and Its Association With Peripheral Diabetic Neuropathy

Aristotle University Of Thessaloniki1 site in 1 country50 target enrollmentNovember 20, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Type 1
Sponsor
Aristotle University Of Thessaloniki
Enrollment
50
Locations
1
Primary Endpoint
Targeted proteomic analysis in children with DT1 (levels of certain plasma proteomics such as sorbitol, fructose, myo-inositol, scyllo-inositol, serine, lysine, tertadecanoic, palmitic, stearic, eicosanoic fatty acids)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The aim of the present study is to investigate a targeted proteomic analysis in plasma of children - of Greek origin- with type 1 diabetes (DT1) and its correlation with the electrophysiological findings that accompany diabetic peripheral neuropathy.

Diabetic neuropathy is the most frequent chronic complication in adults with DT1 and rarely appears in childhood. Nevertheless, cases of acute mononeuritis have been described at the time of diagnosis of DT1. According to recent reports several biomarkers, including proteomic analysis, have been proposed for the early detection of peripheral neuropathy in children and young adults with T1DM.

In the present study the researchers will attempt to investigate the role of biomarkers with targeted proteomic analysis in the plasma of children with DT1 in combination with an electrophysiological study, which includes a nerve conduction study, to detect early diabetic peripheral neuropathy, before the appearance of clinical manifestations.

Registry
clinicaltrials.gov
Start Date
November 20, 2018
End Date
January 20, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Assimina Galli-Tsinopoulou

Professor

Aristotle University Of Thessaloniki

Eligibility Criteria

Inclusion Criteria

  • Children with confirmed DT1 under insulin substitution therapy
  • Age 5-10 years
  • Good glycemic control with HbA1c ≤ 7.0%
  • Prepubertal patients
  • Absence of other diseases
  • Signed informed consent of the parents or guardians of patients

Exclusion Criteria

  • Presence of organic cause for neuropathy
  • Presence of other chronic disease
  • Poor glycemic control

Outcomes

Primary Outcomes

Targeted proteomic analysis in children with DT1 (levels of certain plasma proteomics such as sorbitol, fructose, myo-inositol, scyllo-inositol, serine, lysine, tertadecanoic, palmitic, stearic, eicosanoic fatty acids)

Time Frame: 2018-2020

Secondary Outcomes

  • Electrophysiological study(2018-2020)

Study Sites (1)

Loading locations...

Similar Trials